ArticleThe Journal of clinical endocrinology and metabolism2025
The Combination of Aromatase Inhibitors and GH Treatment for Idiopathic Short Stature in Male Adolescents.
Article in The Journal of clinical endocrinology and metabolism, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 3 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Charting the growth of idiopathic short stature research: a 32-year bibliometric study of global advances.Frontiers in endocrinology · 2025Pooled it
- Diagnosis and management of Silver-Russell syndrome: second international consensus statement.Nature reviews. Endocrinology · 2026Review
- Effectiveness and Safety of Hormonal Treatments in Children with Growth Disorders: A Systematic Review of Clinical Evidence.Clinics and practice · 2026Review
Corrections and comments
- Erratum issued
Authors and funding
4 authors.
Funding
Abstract
objectiveTo evaluate the efficacy and safety in adolescent boys with idiopathic short stature (ISS) when treated with third-generation aromatase inhibitors (AIs), the combination of letrozole or anastrozole with recombinant human GH (rhGH), and compare adult height (AHt) augmentation following the treatment with rhGH combined with AIs or GnRH analog (GnRHa) in male adolescents with ISS.
methodWe collected data from adolescent boys with ISS and a bone age ≥ 13 years who received treatment at Tongji Hospital, Huazhong University of Science and Technology from May 2017 to June 2023. Patients were allocated into the combined letrozole and rhGH group, the combined anastrozole and rhGH group, and the combined GnRHa and rhGH group based on their treatment. Three groups were matched by propensity score matching. There were 32 cases in each group. Follow-up was conducted every 3 months until AHt. Adverse events were monitored throughout.
resultsThe SD scores of AHt adjusted for target height in the letrozole, anastrozole, and GnRHa groups were 0.60 ± 0.28, 0.81 ± 0.34, and 0.48 ± 0.17, respectively. Compared with the letrozole and GnRHa groups, the anastrazole and rhGH combination group showed the most significant increase in AHt (P < .01). The abnormal monitoring indicators of the AIs group gradually returned to normal following the termination of treatment.
conclusionFor adolescent males with ISS and a bone age ≥ 13 years, the combination of AI and rhGH significantly increased the AHt. Finally, our analyses showed that anastrozole exerts more significant effects with regard to augmenting AHt with fewer adverse reactions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.